Question from Deputy Ken O'Flynn - PQ 10655-26

To ask the Minister for Health whether the Health Service Executive or her Department has prepared, commissioned, received, or reviewed any cost-effectiveness analysis, budget impact analysis, or economic model relating to the use of GLP-1 receptor agonist medicines for obesity or weight management, including semaglutide and tirzepatide; whether any such analysis includes modelling of downstream cost offsets relating to type 2 diabetes, cardiovascular disease, or related complications; and if so, to provide the title, authoring body, and completion date of each such analysis.